

Supplementary Table 5. Treatments received (patient reported)

Variable	MF (n = 39)	PV (n = 25)	ET (n = 41)	All (n = 105)	p value
Treatments ever received					
Aspirin	17 (43.59)	21 (84.00)	34 (82.93)	72 (68.57)	0.0001
Antihistamines	6 (15.38)	1 (4.00)	4 (9.76)	11 (10.48)	0.3955
Bone marrow transplant or stem cell transplant	9 (23.08)	0	1 (2.44)	10 (9.52)	0.0010
Phlebotomy	3 (7.69)	23 (92.00)	2 (4.88)	28 (26.67)	< 0.0001
Removal of spleen	4 (10.26)	0	2 (4.88)	6 (5.71)	0.1902
Antidepressants	7 (17.95)	0	1 (2.44)	8 (7.62)	0.0121
Anabolic steroids	8 (20.51)	0	2 (4.88)	10 (9.52)	0.0124
Corticosteroids	11 (28.21)	0	1 (2.44)	12 (11.43)	0.0002
Hydroxyurea	19 (48.72)	20 (80.00)	33 (80.49)	72 (68.57)	0.0034
Ruxolitinib	25 (64.10)	0	2 (4.88)	27 (25.71)	< 0.0001
Other JAK inhibitors	1 (2.56)	0	0	1 (0.95)	0.6095
Anti-coagulants/blood thinners (e.g., heparin, warfarin)	5 (12.82)	2 (8.00)	4 (9.76)	11 (10.48)	0.8489
Interferon (e.g., IFN- α)	0	0	1 (2.44)	1 (0.95)	1.0000
Anagrelide	4 (10.26)	6 (24.00)	13 (31.71)	23 (21.90)	0.0652
Busulfan	2 (5.13)	0	0	2 (1.90)	0.1907
Transfusion	20 (51.28)	1 (4.00)	3 (7.32)	24 (22.86)	< 0.0001
Radiation therapy	3 (7.69)	0	1 (2.44)	4 (3.81)	0.3594
Investigational drug in the context of a clinical trial	2 (5.13)	0	1 (2.44)	3 (2.86)	0.6162
Androgens (e.g. danazol)	3 (7.69)	0	2 (4.88)	5 (4.76)	0.3625
Iron replacement therapies	11 (28.21)	0	4 (9.76)	15 (14.29)	0.0040
Psychological therapy	10 (25.64)	0	8 (19.51)	18 (17.14)	0.0258
None of the above	2 (5.13)	0	1 (2.44)	3 (2.86)	0.6162

Values are presented as number (%).

MF, myelofibrosis; PV, polycythemia vera; ET, essential thrombocythemia; IFN- α , interferon α .